**PD-1/PD-L1 inhibitors vs. chemotherapy for previously treated advanced** **gastroesophageal cancer: A meta-analysis of randomized controlled trials**

Maoxi Zhong1,2,3, Xiaozhu Zeng1,2,3, Jinmin Xue1,2,3, Yubing Yue1,2,3, Yuxi Zhu1,2,3\*

1 *Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China*


2 *Department of Oncology, Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China*

*3Chongqing Clinical Cancer Research Center, Chongqing, P.R. China*


**\* Correspondence:** Yuxi Zhu E-mail: [zhuyuxi@hospital.cqmu.edu.cn](mailto:zhuyuxi@hospital.cqmu.edu.cn)

**supplementary Fig.1** Forest plot of risk ratios for objective response rate (ORR) between PD-1/PD-L1 inhibitors and chemotherapy/placebo in subgroups

**(a)** ORR in the squamous cell carcinoma subgroup


****

**(b)** ORR in the adenocarcinoma subgroup




**supplementary Fig.2** Forest plot of hazard ratios for progression-free survival (PFS) between PD-1/PD-L1 inhibitors and chemotherapy/placebo in subgroups

**(a)** PFS in the squamous cell carcinoma subgroup




**(b)** PFS in the adenocarcinoma subgroup




**supplementary Fig.3** Forest plot of hazard ratios of overall survival (OS) between PD-1/PD-L1 inhibitors and chemotherapy/placebo in subgroups

**(a)** OS in the squamous cell carcinoma subgroup



**(b)** OS in the adenocarcinoma subgroup



**supplementary Table 1** Any grade treatment-related adverse events of the PD-1/PD-L1 inhibitor group vs. the chemotherapy group

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **TRAEs** | **No. of studies** | **No. of patients** | **RR** | **Min**  **95%CI** | **Max 95%CI** | **P-value** |
| Fatigue | 5 | 2139 | 0.48 | 0.38 | 0.61 | 0.000 |
| Nausea | 5 | 2406 | 0.19 | 0.10 | 0.34 | 0.000 |
| Diarrhea | 6 | 2587 | 0.30 | 0.17 | 0.54 | 0.000 |
| Anemia | 6 | 2587 | 0.16 | 0.09 | 0.26 | 0.000 |
| Neutrophil count decreased | 6 | 2587 | 0.07 | 0.03 | 0.14 | 0.000 |
| WBC count decreased | 5 | 2017 | 0.08 | 0.04 | 0.18 | 0.000 |
| Bone marrow toxicity | 2 | 629 | 0.05 | 0.01 | 0.40 | 0.004 |
| Hypothyroidism | 4 | 1809 | 7.85 | 4.14 | 14.86 | 0.000 |
| Lung infection | 3 | 1199 | 3.08 | 0.22 | 43.16 | 0.404 |
| Events leading to death | 4 | 1836 | 0.89 | 0.38 | 2.08 | 0.786 |

**supplementary Table 2** Grade 3-5 treatment-related adverse events of the PD-1/PD-L1 inhibitor group vs. the chemotherapy group

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **TRAEs** | **No. of studies** | **No. of patients** | **RR** | **Min 95%CI** | **Max**  **95%CI** | **P-value** |
| Fatigue | 5 | 2139 | 0.46 | 0.20 | 1.07 | 0.072 |
| Nausea | 5 | 2406 | 0.17 | 0.05 | 0.59 | 0.005 |
| Diarrhea | 6 | 2587 | 0.31 | 0.15 | 0.66 | 0.002 |
| Anemia | 6 | 2587 | 0.28 | 0.15 | 0.53 | 0.000 |
| Neutrophil count decreased | 5 | 1977 | 0.04 | 0.01 | 0.10 | 0.000 |
| WBC count decreased | 4 | 1407 | 0.03 | 0.01 | 0.11 | 0.000 |
| Bone marrow toxicity | 2 | 629 | 0.08 | 0.01 | 0.60 | 0.014 |
| Hypothyroidism | 4 | 1809 | - | - | - | - |
| Lung infection | 3 | 1199 | 1.91 | 0.17 | 21.96 | 0.605 |